Giulia Cerretti

Padova, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.

Journal: Neuro-oncology advances

Published: April 17, 2026

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Journal: Neuro-oncology advances

Published: September 18, 2025

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Journal: Trials

Published: February 17, 2025

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.

Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience.

Journal: Journal of neuro-oncology

Published: January 27, 2025

Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].

Corrigendum to "PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives" [Cancer Treat. Rev. 131 (2024) 102850].

Journal: Cancer treatment reviews

Published: December 21, 2024

PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives.

PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives.

Journal: Cancer treatment reviews

Published: September 23, 2024

Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage.

Relationship between glioblastoma location and O6-methylguanine-DNA methyltransferase promoter methylation percentage.

Journal: Brain communications

Published: June 10, 2024

Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion.

Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a GOPC::ROS1 fusion.

Journal: Neuro-oncology advances

Published: June 07, 2024

Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial.

Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial.

Journal: Frontiers in oncology

Published: October 12, 2023

Spinal ependymoma in adults: from molecular advances to new treatment perspectives.

Spinal ependymoma in adults: from molecular advances to new treatment perspectives.

Journal: Frontiers in oncology

Published: September 24, 2023

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.

Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.

Journal: The oncologist

Published: August 24, 2023

Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma.

Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma.

Journal: Critical reviews in oncology/hematology

Published: August 06, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026